Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ekkehart Ladda"'
Autor:
Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were rando
Externí odkaz:
https://doaj.org/article/b93eb5cc3e364be681372848cc75b63c
Autor:
Mattea Reinisch, Michael Untch, Rolf Mahlberg, Toralf Reimer, Thomas Hitschold, Frederik Marmé, Mustafa Aydogdu, Sabine Schmatloch, Hans-Joachim Lück, Marcus Schmidt, Ekkehart Ladda, Bruno Valentin Sinn, Peter Klare, Wolfgang Janni, Christian Jackisch, Carsten Denkert, Sabine Seiler, Thomas Göhler, Laura Michel, Nicole Burchardi, Elmar Stickeler, Julia Rey, Nicole Klutinus, Volker Möbus, Sibylle Loibl
Publikováno v:
Breast, Vol 66, Iss , Pp 110-117 (2022)
Background: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into th
Externí odkaz:
https://doaj.org/article/916f38f5626a45b9afb718606995934e
Autor:
Frederik Marmé, Helmut Forstbauer, Jens Huober, Gbg, Bruno Valentin Sinn, Michael Untch, Jenny Furlanetto, Christian Jackisch, Jens-Uwe Blohmer, Hans-Joachim Lück, Knut Engels, Ago-B, Grischa Wachsmann, Ekkehart Ladda, Nicole Burchardi, Elmar Stickeler, Sabine Schmatloch, Sibylle Loibl, Mattea Reinisch, Theresa Link, Volker Möbus, Carsten Denkert, Eva-Maria Grischke, Peter Klare, Marcus Schmidt, Christine Solbach, Andreas Schneeweiss, Julia Rey, Wolfgang Janni
Publikováno v:
European Journal of Cancer. 156:138-148
Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients an
Autor:
Christine Solbach, Andreas Schneeweiss, Elmar Stickeler, Hans-Joachim Lueck, Julia Rey, Ekkehart Ladda, Sabine Schmatloch, Nicole Burchardi, Toralf Reimer, Marcus Schmidt, Sibylle Loibl, Bruno Valentin Sinn, Jenny Furlanetto, Volker Moebus, Jens Huober, Frederik Marmé, Michael Untch, Peter Klare, Mattea Reinisch, Theresa Link
Publikováno v:
Journal of Clinical Oncology. 38:516-516
516 Background: GAIN-2 (NCT01690702) compared efficacy and safety of intense, dose-dense epirubicin, nab-paclitaxel, and cyclophosphamide (iddEnPC) vs dose-dense, dose-tailored epirubicin/ cyclophosphamide followed by dose-dense, dose-tailored doceta
Autor:
F Marmé, HJ Lück, R.J.C. Mahlberg, M. Aydogdu, Martina Schmidt, N Klutinus, Michael Untch, Elmar Stickeler, Peter Klare, Ekkehart Ladda, Mattea Reinisch, Bruno Valentin Sinn, Sabine Schmatloch, Volker Möbus, T. Reimer, S. Loibl, C. Jackisch, T. Hitschold, Sabine Seiler, J. Rey
Publikováno v:
Annals of Oncology. 31:S44
Autor:
Jenny Furlanetto, Marcus Schmidt, Frederik Marmé, Peter Klare, Michael Untch, Peter A. Fasching, Volker Moebus, Stefanie Noeding, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Volkmar Müller, Bruno Valentin Sinn, Wolfgang Janni, Sibylle Loibl, Toralf Reimer, Gunter von Minckwitz, Ekkehart Ladda, Nicole Burchardi
Publikováno v:
Journal of Clinical Oncology. 36:568-568
568Background: GAIN-2 compares the effectiveness and safety of a predefined idd regimen (EnPC) vs. a dd regimen with modification of single doses depending on individual hematological and non-hemat...